Skip to main content
    H

    HCW Biologics Inc (HCWB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.79
    +0.01 (+1.54%)

    Market Cap: $1.73M

    Last updated: Nov 17, 2026 at 10:58 AM ET

    HCW Biologics Inc (HCWB) Financials: Revenue, Profit and Cash Flow

    Updated Nov 16, 2026. Financial statements from company filings, amounts in US dollars.

    HCW Biologics reported revenue of $54.23K for the fiscal year ended Dec 31, 2025, down 97.9% from the year before. That year, net income was -$7.96M with a net margin of -14677.1%, operating cash flow was -$13.39M and free cash flow was -$13.39M. The quarter ended Sep 30, 2026 had revenue of $55.46K and net income of -$3.22M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue fell from $4.10M, a compound annual decline of 57.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$54.23K-97.9%20.0%-24270.7%-14677.1%
    Dec 2024$2.57M-9.7%37.4%-1147.6%-1169.7%
    Dec 2023$2.84M-57.7%19.7%-905.0%-879.5%
    Dec 2022$6.72MN/A38.5%-224.3%-221.7%
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$4.10MN/A100.0%-142.1%-141.5%
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$54.23K$2.57M$2.84M$6.72M$0$4.10M$0
    Cost of revenue$43.39K$1.61M$2.28M$4.14M$0$0$421.82K
    Gross profit$10.85K$959.40K$560.36K$2.59M$0$4.10M-$421.82K
    Research and development$5.44M$6.39M$7.68M$9.34M$8.17M$7.26M$5.14M
    Operating income-$13.16M-$29.46M-$25.72M-$15.08M-$13.37M-$5.82M-$7.37M
    Net income-$7.96M-$30.02M-$24.99M-$14.90M-$12.86M-$5.80M-$7.29M
    EBITDA-$11.00M-$28.19M-$23.58M-$14.06M-$12.32M-$5.23M-$6.87M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$55.46K$135.57K$6.54M$27.01K$15.61K$6.55K$5.07K$394.80K$426.42K$618.85K$1.13M$1.32M
    Gross profit$28.12K-$93.89K$6.53M$5.40K$3.12K$1.31K$1.01K$78.96K$85.28K$180.41K$614.75K$252.65K
    Operating income-$2.59M-$3.17M$3.24M-$4.44M-$3.29M-$3.46M-$1.97M-$3.14M-$3.68M-$15.14M-$7.49M-$10.77M
    Net income-$3.22M-$5.22M$3.47M$719.23K-$4.55M-$1.93M-$2.20M-$3.37M-$3.90M-$15.28M-$7.47M-$10.68M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $6.81M exceeded cash and equivalents by $4.86M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$24.52M$30.24M$28.51M$46.81M$53.51M$15.40M$10.07M
    Current assets$2.28M$5.70M$6.40M$34.07M$40.48M$12.15M$8.03M
    Cash and equivalents$1.95M$4.67M$3.60M$22.33M$11.73M$8.46M$7.36M
    Total liabilities$21.76M$37.01M$15.05M$9.38M$2.32M$1.00M$1.07M
    Short-term debt$6.81M$6.31M$0$6.41M$1.80M$567.31KN/A
    Long-term debtN/A$7.38M$6.30M$6.41M$0N/AN/A
    Shareholder equity$2.76M-$6.77M$13.46M$37.43M$51.19M-$16.72M$9.00M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$25.13M$26.77M$27.34M$24.52M$25.45M$28.91M$26.29M$30.24M$26.56M$26.82M$30.43M$28.51M
    Total liabilities$18.30M$19.34M$21.58M$21.76M$27.55M$28.96M$34.85M$37.01M$36.53M$33.12M$21.69M$15.05M
    Cash and equivalents$955.46K$741.32K$1.23M$1.95M$1.10M$2.44M$1.11M$4.67M$998.22K$1.16M$4.08M$3.60M
    Shareholder equity$6.82M$7.43M$5.76M$2.76M-$2.11M-$51.97K-$8.56M-$6.77M-$9.97M-$6.30M$8.74M$13.46M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$13.39M-$14.23M-$22.51M-$10.39M-$10.98M-$10.43M-$6.77M
    Capital expenditures$0$261.62K$6.20M$10.28M$47.26K$186.68K$1.46M
    Free cash flow-$13.39M-$14.49M-$28.72M-$20.66M-$11.02M-$10.62M-$8.23M
    Dividends paidN/AN/AN/AN/A$2.82MN/AN/A
    Share repurchases$1.21M$638.04K$0$190.55K$0N/AN/A
    Investing cash flow$0-$261.62K$3.80M$14.71M-$35.02M-$186.68K-$1.46M
    Financing cash flow$10.67M$15.57M-$14.53K$6.27M$49.27M$11.72M$13.45M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.62M-$3.97M-$1.58M-$3.36M-$3.24M-$3.28M-$3.51M-$2.83M-$2.93M-$4.86M-$3.60M-$3.89M
    Capital expendituresN/AN/A$4$3$1$3$4$113.41K$37.06K$18.57K$129.71K$3.72M
    Free cash flowN/AN/A-$1.58M-$3.36M-$3.24M-$3.28M-$3.51M-$2.95M-$2.96M-$4.88M-$3.73M-$7.61M
    Last 12 quarters

    Frequently Asked Questions About HCWB

    What is HCW Biologics' annual revenue?

    HCW Biologics reported revenue of $54.23K for the fiscal year ended Dec 31, 2025.

    How fast is HCW Biologics' revenue growing?

    Revenue was down 97.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -79.9%.

    Is HCW Biologics profitable?

    No. HCW Biologics reported net income of -$7.96M for the fiscal year ended Dec 31, 2025, with a net margin of -14677.1%.

    How much free cash flow does HCWB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.39M minus capital expenditures of $0 produced free cash flow of -$13.39M.

    How much debt does HCW Biologics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $6.81M and cash and equivalents of $1.95M.